Renalytix AI (GB:RENX) has released an update.
Renalytix, a leader in kidney health bioprognosis, has announced its total issued share capital of 165,925,513 Ordinary Shares, each with voting rights at company meetings. Shareholders can use this number as a benchmark for disclosing changes in their stake in the company according to regulatory rules. The firm’s KidneyIntelX test aims to improve outcomes for patients with Type 2 diabetes and chronic kidney disease by predicting disease progression.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
